Literature DB >> 9432044

Incidence of AML1/ETO fusion transcripts in patients entered into the MRC AML trials. MRC Adult Leukaemia Working Party.

S E Langabeer1, H Walker, J R Rogers, A K Burnett, K Wheatley, D Swirsky, A H Goldstone, D C Linch.   

Abstract

Acute myeloid leukaemia (AML) with the t(8;21)(q22;q22) is deemed to be a 'good-risk' disease. 396 patients with AML at diagnosis were screened for the presence of t(8;21) and AML1/ETO fusion transcripts by cytogenetic and RT-PCR techniques respectively. 32 cases of t(8;21) were detected, all of which were also PCR positive. A further 19 cases were detected at the molecular level, predominantly but not exclusively in M1 and M2 FAB types. Approximately 12% of all new cases of AML are estimated to have AML1/ETO fusion transcripts and it is suggested that molecular screening should be performed in all cases with the possible exception of the M3 FAB type.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9432044     DOI: 10.1046/j.1365-2141.1997.4663270.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  14 in total

1.  Deletion of an AML1-ETO C-terminal NcoR/SMRT-interacting region strongly induces leukemia development.

Authors:  Ming Yan; Sebastien A Burel; Luke F Peterson; Eiki Kanbe; Hiromi Iwasaki; Anita Boyapati; Robert Hines; Koichi Akashi; Dong-Er Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-29       Impact factor: 11.205

2.  Classification of acute leukaemia: the need to incorporate cytogenetic and molecular genetic information.

Authors:  B J Bain
Journal:  J Clin Pathol       Date:  1998-06       Impact factor: 3.411

3.  RNA-mediated gene fusion in mammalian cells.

Authors:  Sachin Kumar Gupta; Liming Luo; Laising Yen
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-11       Impact factor: 11.205

4.  Geographic heterogeneity of the AML1-ETO fusion gene in Iranian patients with acute myeloid leukemia.

Authors:  Saeedeh Ghazaey Zidanloo; Abasalt Hosseinzaeh Colagar
Journal:  Rep Biochem Mol Biol       Date:  2014-10

5.  Disruption of the NHR4 domain structure in AML1-ETO abrogates SON binding and promotes leukemogenesis.

Authors:  Eun-Young Ahn; Ming Yan; Oxana A Malakhova; Miao-Chia Lo; Anita Boyapati; Hans Beier Ommen; Robert Hines; Peter Hokland; Dong-Er Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-24       Impact factor: 11.205

6.  Attenuation of AML1-ETO cellular dysregulation correlates with increased leukemogenic potential.

Authors:  Russell C DeKelver; Ming Yan; Eun-Young Ahn; Wei-Jong Shia; Nancy A Speck; Dong-Er Zhang
Journal:  Blood       Date:  2013-02-20       Impact factor: 22.113

7.  An activated receptor tyrosine kinase, TEL/PDGFbetaR, cooperates with AML1/ETO to induce acute myeloid leukemia in mice.

Authors:  Jay L Grisolano; Julie O'Neal; Jennifer Cain; Michael H Tomasson
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-24       Impact factor: 11.205

8.  RUNX1-ETO induces a type I interferon response which negatively effects t(8;21)-induced increased self-renewal and leukemia development.

Authors:  Russell C DeKelver; Benjamin Lewin; Stephanie Weng; Ming Yan; Joseph Biggs; Dong-Er Zhang
Journal:  Leuk Lymphoma       Date:  2013-07-25

9.  Multiplex RT-PCR for the detection of leukemia-associated translocations: validation and application to routine molecular diagnostic practice.

Authors:  Manuel Salto-Tellez; Suresh G Shelat; Bernice Benoit; Hanna Rennert; Martin Carroll; Debra G B Leonard; Peter Nowell; Adam Bagg
Journal:  J Mol Diagn       Date:  2003-11       Impact factor: 5.568

10.  Monitoring AML1-ETO and CBFbeta-MYH11 transcripts in acute myeloid leukemia.

Authors:  John A Liu Yin; Lindsay Frost
Journal:  Curr Oncol Rep       Date:  2003-09       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.